As of 2025-05-03, the Fair Value of CRISPR Therapeutics AG (CRSP) is -21.20 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 38.25 USD, the upside of CRISPR Therapeutics AG is -155.44%.
With the market price of 38.25 USD and our fair value calculation, CRISPR Therapeutics AG (CRSP) is not a good investment. Investing in CRSP stocks now will result in a potential loss of 155.44%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -348.90 | 377.70 | -650.20 | -153.61 | -366.25 | -228.25 |
| YoY growth | -621.52% | 208.25% | -272.15% | 76.37% | -138.43% | -149.49% |
| Market Cap (mil) | 3,303.27 |
| P/E | |
| Forward P/E |
| EPS | -4.24 |
| Avg earnings growth rate | -149.49% |
| TTM earnings | -366.25 |